Fauci’s EXPENSIVE Gilead Drug Remdesivir FAILS Another Test

Sharing is Caring!

by Natura Naturans

A new study is raising fresh questions about the efficacy of Gilead Sciences Inc’s anti-viral medication remdesivir in COVID-19 patients.

A randomized, controlled trial of remdesivir in 584 moderately ill COVID-19 patients hospitalized with pneumonia yielded disappointing results in research published on Friday in JAMA. Compared to standard care without remdesivir, a 10-day course of the drug did not show a statistically significant effect on disease course at 11 days after treatment started, the study found.


You have to wonder why they keep pushing this drug that has failed EVERY study done on it. Here is the first study:

A potential antiviral drug for the coronavirus has reportedly failed in its first randomised clinical trial.

There had been widespread hope that remdesivir could treat Covid-19.

But a Chinese trial showed that the drug had not been successful, according to draft documents accidentally published by the World Health Organization.

The drug did not improve patients’ condition or reduce the pathogen’s presence in the bloodstream, it said.

When will we have a vaccine?
The US firm behind the drug, Gilead Sciences, said the document had mischaracterised the study.

What do we know about the study?
News of the failed trial spread after the WHO posted details on its clinical trials database, before it was removed. The WHO has since confirmed the draft report was mistakenly uploaded.

It showed that researchers studied 237 patients, administering the drug to 158 and comparing their progress with the remaining 79, who received a placebo.

After a month, 13.9% of the patients taking the drug had died compared to 12.8% of those receiving the placebo. The trial was stopped early because of side-effects.

“Remdesivir was not associated with clinical or virological benefits,” the summary states.






Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.